| pubmed-article:20095806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0079633 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:20095806 | lifeskim:mentions | umls-concept:C0023983 | lld:lifeskim |
| pubmed-article:20095806 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20095806 | pubmed:dateCreated | 2010-8-9 | lld:pubmed |
| pubmed-article:20095806 | pubmed:abstractText | Glucocorticosteroids (GS) are standard treatment of multiple sclerosis (MS) relapse, but no superiority of any commonly used doses is known. The aim of present study was to evaluate mRNA expression for two cytokines: IL-6 and IL-8. Ethylenediaminetetraacetic acid blood samples from 35 MS relapse patients were obtained before therapy, after 7, 14 days, and 3 months from treatment start (500 versus 1000 mg for 5 days). Significant neurological improvement measured with EDSS was independent to GS dose. Changes of mRNA cytokines expression were more evident in higher dose group but for IL-6 mainly in females. | lld:pubmed |
| pubmed-article:20095806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20095806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20095806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20095806 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20095806 | pubmed:issn | 1532-2513 | lld:pubmed |
| pubmed-article:20095806 | pubmed:author | pubmed-author:CzlonkowskaAn... | lld:pubmed |
| pubmed-article:20095806 | pubmed:author | pubmed-author:CzlonkowskiAn... | lld:pubmed |
| pubmed-article:20095806 | pubmed:author | pubmed-author:GromadzkaGraz... | lld:pubmed |
| pubmed-article:20095806 | pubmed:author | pubmed-author:KurowskaKatar... | lld:pubmed |
| pubmed-article:20095806 | pubmed:author | pubmed-author:Mirowska-Guze... | lld:pubmed |
| pubmed-article:20095806 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20095806 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:20095806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20095806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20095806 | pubmed:pagination | 416-21 | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:meshHeading | pubmed-meshheading:20095806... | lld:pubmed |
| pubmed-article:20095806 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20095806 | pubmed:articleTitle | Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients. | lld:pubmed |
| pubmed-article:20095806 | pubmed:affiliation | 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland. | lld:pubmed |
| pubmed-article:20095806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20095806 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
